Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Builders FirstSource, Raises Price Target to $103

Barclays maintains Builders FirstSource (NYSE:BLDR) with a Overweight and raises the price target from $98 to $103.

byBenzinga Newsdesk

December 15, 2021

1 minute read

Barclays maintains Builders FirstSource (NYSE:BLDR) with a Overweight and raises the price target from $98 to $103.

CJS Securities Downgrades John Wiley & Sons to Market Perform

By Benzinga Newsdesk

Today, 6:29 AM

CJS Securities analyst Daniel Moore downgrades John Wiley & Sons (NYSE:WLY) from Market Outperform to Market Perform.

WLY

House Democrats Are Caucusing At 10:30 a.m. EDT In Washington DC

By Benzinga Newsdesk

Today, 6:29 AM

-Bloomberg citing Punchbowl

SPY

Novo Integrated Sciences Launches New Patient Portal App Giving Patients More Control Over Their Healthcare

By Rachael Green

Today, 6:29 AM

The ‘new’ reality of the COVID-19 pandemic, ongoing advancements in medical technology, inter-connectivity, and blockchain technology, are all key drivers in the global healthcare system making critical early adoptions of many overdue improvements.

CDXFF

$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,400 Today

By Benzinga Insights

Today, 6:29 AM

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 8.2% on an annualized basis producing an average annual return of 14.17%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.97 billion.

VRTX

Barclays Maintains Overweight on Builders FirstSource, Raises Price Target to $103

Related Posts

CJS Securities Downgrades John Wiley & Sons to Market Perform

House Democrats Are Caucusing At 10:30 a.m. EDT In Washington DC

Novo Integrated Sciences Launches New Patient Portal App Giving Patients More Control Over Their Healthcare

$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,400 Today